Lupus drug benlysta proves safe and effective in large Real-World trial
NCT ID NCT03370263
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety and effectiveness of Benlysta, a medication for systemic lupus erythematosus (SLE), in over 1,500 patients in everyday medical practice. Researchers tracked participants for 52 weeks, monitoring side effects, disease activity, and quality of life. The goal was to gather real-world data to ensure the drug is used properly and safely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
Hiroshima, 730-0001, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new biologic tame lupus flares?
- Could a single injection tame lupus and Sjögren's?
- Can a single infusion tame tough lupus?
- Can a single drug calm three different autoimmune diseases? a new trial puts ATG-201 to the test.
- Can genetics and environment explain lupus in the gullah population?
- Can a smartphone app bridge the lupus care gap for women of color?